Acceder

Kodak - Chapter 11: Quiebra

4,34K respuestas
Kodak - Chapter 11: Quiebra
Kodak - Chapter 11: Quiebra
Página
91 / 546
#721

Re: Kodak - Chapter 11: Quiebra

Hey Ricardo, pero .. ¿tienes fundamentales de GNBT y Cerp recientes.. ? o te basas todo en A.Tecnico.De KV te puedo comentar mxisimo de fndamentales po de a.Tecnico no tanto,no soy experto en ello po se ve una curva de inicio alcista, bno a mis ojos claro, po si tu tienes mas experiencia y la miras,comentame tu opinion.Solo te digo q compre a 0.05 y en 6 semanas se me puso en 0.28 la venia vigilando, solo q mi target es otro y en OTC se hace dificl hacer intradia, por el riesgo del poco volumen.Ahora lleva plana 5 sesiones en 0.13.Creo en unos meses podria llegar a cerca de 1.00usd y en pocas semans encima de 0.32, q es su resistecia, pues hay varios Inversionistas pujando por ella y .. etc, etc.

#722

Re: Kodak - Chapter 11: Quiebra

pienso lo mismo en gnbt y cerp van a ser una disparada y veo la misma posibilidad en kv

#723

Re: Kodak - Chapter 11: Quiebra

HOLA RICARDO QUE OPINAS DE ESTA NOTICIA.Y
K-V Pharmaceutical Co. (KVPBQ, KVPHQ) won an extension to keep exclusive control of its restructuring case, but a bankruptcy judge left the door open for creditors to file a rival proposal.
Judge Allan L. Gropper of the U.S. Bankruptcy Court in New York Tuesday extended K-V's exclusive right to file a Chapter 11 plan through June 17. So- called exclusive periods protect a firm restructuring under Chapter 11 from outsiders who may look to interfere with the reorganization process for their own benefit.
Judge Gropper, however, said his order "shall not in any way impair or prejudice the right or ability of any party in interest, including, without limitation, the committee, to seek to terminate the debtors' exclusive filing period."
The ruling allows the committee representing K-V's unsecured creditors to terminate the drug maker's exclusive control in order to file its own competing plan. The committee said last week in court papers that it "was in the process of formulating" its own plan, one that will pay senior note holders in full.
K-V is trying to exit bankruptcy under the control of hedge fund Silver Point Capital and other investors. Silver Point and Whitebox Advisors, along with Boston mutual-fund company Pioneer Investment Management, have agreed to swap some $225 million in secured notes for an 82% stake in the reorganized pharmaceutical company.
But the creditors say the Silver Point plan substantially undervalues K-V. A series of recent developments have boosted the sales of Makena, K-V's flagship premature birth drug. The creditors also note that the pending launch of two other drugs has K-V poised for significant growth.
K-V's future depends on the success of premature-birth drug Makena, which it purchased from drug maker Hologic Inc. (HOLX) in 2008.
The company won "orphan drug" status for Makena, giving it the exclusive right to make the drug for seven years. But it initially marketed the drug at $1,500 per shot, a price that prompted howls of protests from women, obstetricians and members of Congress.
That misstep resulted in the FDA's decision to refrain from taking action against so-called compounding pharmacies that make far-cheaper premature-birth drugs using the same active ingredient as Makena's. K-V eventually lowered the price. It also led to Hologic trying to regain the rights to the drug, but the two sides recently settled their dispute.
K-V sued the FDA in Washington earlier this year over its decision, but a federal judge dismissed the suit. K-V has appealed.

#724

Re: Kodak - Chapter 11: Quiebra

no se ingles pero me guista la accion trato de comprar pero nadie vende

#725

Re: Kodak - Chapter 11: Quiebra

he compradop de los 2 tipos de una 5000 y de la otra 55000 acciones no hay vendedores

#726

Re: Kodak - Chapter 11: Quiebra

no hay acciones en venta de kv pharmaceutica he puesto orden y le he subido varias veces el limite no hay venta es es bueno apunto de emerger del chapter 11

#727

Re: Kodak - Chapter 11: Quiebra

Habla con tu brokerage, algunos no la tienen en cartera o se les cae la conexion con el intermediario en OTC. Revisa y lee en la web de KV sobre la Clase B, son menos fuertes y valiosas, si estoy equivocado comentamelo, la B, cotizan en Alemania tambien.En la informacion q te he enviado dice-- El Juez protegera a todos los partes, por tanto interpreto que...Protegera a los accionista comunes-- supongo q hasta de un fuerte split.La fuente es confiable.Hay varios Fondos de Inversion interesados en ella y mas todavia pujando por ella, su disparada podria ser inminente, es decir en unos meses.En el Chart comienza a definir un suelo redondeado, en aun corto tramo alcista.

#728

Re: Kodak - Chapter 11: Quiebra

el juez que lleva el caso es el mismo que ve el chapter 11 de kodak